Semma Therapeutics

Read more
Bastiano Sanna's photo - President & CEO of Semma Therapeutics

President & CEO

Bastiano Sanna

CEO Approval Rating

88/100

Est. Annual Revenue
$7M
Agree?
Est. Employees
35
Agree?

SEMMA THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Semma Therapeutics's company profile
Bastiano Sanna's photo - President & CEO of Semma Therapeutics

Bastiano Sanna

President & CEO

88/100
35
$162.9M
$7M
View Profile
1
Semma Therapeutics's Competitor - ViaCyte logo
Michael J. Yang's photo - President & CEO of ViaCyte

Michael J. Yang

President & CEO

85/100
60
$216.8M
$25M
View Profile
2
Semma Therapeutics's Competitor - Diamyd Medical logo
Ulf Hannelius's photo - President & CEO of Diamyd Medical

Ulf Hannelius

President & CEO

88/100
63
- -
$ < 1M
View Profile
3
Semma Therapeutics's Competitor - Orgenesis logo
Vered Caplan's photo - President & CEO of Orgenesis

Vered Caplan

President & CEO

90/100
231
$23.3M
$24M
View Profile
4
Semma Therapeutics's Competitor - Calimmune logo
Louis Breton's photo - Co-Founder & CEO of Calimmune

Louis Breton

Co-Founder & CEO

74/100
66
$15.9M
$9M
View Profile
5
Semma Therapeutics's Competitor - TiGenix logo
CEO Avatar

Sebastian Wehle

CEO

78/100
80
$71M
$53M
View Profile
6
Semma Therapeutics's Competitor - Regenerative Medical Solutions, Inc. logo
Anthony Kolton's photo - President of Regenerative Medical Solutions, Inc.

Anthony Kolton

President

78/100
18
$2M
$3M
View Profile
7
Semma Therapeutics's Competitor - bluebird bio logo
Nick Leschly's photo - President & CEO of bluebird bio

Nick Leschly

President & CEO

74/100
764
$526.4M
$50.2M
View Profile
8
Semma Therapeutics's Competitor - Osiris Therapeutics logo
CEO Avatar

CEO

- -
360
$127.5M
$150M
View Profile
9
Semma Therapeutics's Competitor - Lineage logo
Brian M. Culley's photo - CEO of Lineage

Brian M. Culley

CEO

87/100
79
$66.7M
$1.8M
View Profile
10
Semma Therapeutics's Competitor - Cesca logo
Chris Xu's photo - Chairman & CEO of Cesca

Chris Xu

Chairman & CEO

77/100
53
$62.6M
$13.1M
View Profile
11
Semma Therapeutics's Competitor - Sernova logo
Philip M. Toleikis's photo - President & CEO of Sernova

Philip M. Toleikis

President & CEO

90/100
9
$29.4M
View Profile
12
Semma Therapeutics's Competitor - Lonza logo
Pierre-Alain Ruffieux's photo - CEO of Lonza

Pierre-Alain Ruffieux

CEO

97/100
13,856
$874M
$5.1B
View Profile

Missing a competitor? Contribute!

ViaCyte is one of Semma Therapeutics's top competitors. ViaCyte was founded in 1999, and its headquarters is in San Diego, California. Like Semma Therapeutics, ViaCyte also works within the Biotechnology sector. ViaCyte has 25 more employees than Semma Therapeutics.

Diamyd Medical is Semma Therapeutics's #2 rival. Diamyd Medical was founded in 1996 in Stockholm, Stockholms län. Diamyd Medical operates in the Biotechnology industry. Diamyd Medical generates $6.1M less revenue than Semma Therapeutics.

Orgenesis is a top competitor of Semma Therapeutics. Orgenesis is a Public company that was founded in Germantown, Maryland in 2008. Orgenesis is in the Biotechnology field. Orgenesis has 76 more employees vs. Semma Therapeutics.

Semma Therapeutics Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Cytosolv, Llc

Nov 2015

Source »
undisclosed
CytoSolv engages in the development of a technology for the cure of diabetic ulcer.

These are all the companies that Semma Therapeutics has acquired. Semma Therapeutics' latest acquisition was Cytosolv, Llc in Nov 2015. CytoSolv engages in the development of a technology for the cure of diabetic ulcer.

Semma Therapeutics Funding History

Since Semma Therapeutics was founded in 2014, it has participated in 3 rounds of funding. In total Semma Therapeutics has raised $162.9M. Semma Therapeutics' last funding round was on Nov 2017 for a total of $113.9M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series B
Nov 2017
$113.9M
Grant
Sep 2016
$5M
Series A
Mar 2015
$44M

Since Semma Therapeutics was founded in 2014, it has participated in 3 rounds of funding. In total Semma Therapeutics has raised $162.9M. Semma Therapeutics' last funding round was on Nov 2017 for a total of $113.9M

Semma Therapeutics Investments

No recent investments found related to Semma Therapeutics

Semma Therapeutics News

September 4, 2019Pharamceutical Technology

bringing diabetes into the pipeline

Vertex Pharmaceutics has announced it has entered into a definitive agreement to acquire Semma Therap... See more »
September 4, 2019BioPharma-Reporter

Vertex adds to deal spree with $950m for biotech seeking diabetes cure

Vertex is set to acquire Semma, which is developing a stem cell curative treatment for type 1 diabete... See more »
July 1, 2019BioPortfolio

Semma Therapeutics Announces PreClinical ProofofConcept in Two Lead Programs in Type 1 Diabetes

Stem cellderived islets successfully reduce insulin requirements in diabetic nonhuman primates Novel ... See more »
May 20, 2019Manufacturing Chemist

Harvard and Semma Therapeutics improve insulin yield from stem cells

The findings, published in Nature, may be used to improve beta cell transplants for patients with typ... See more »
May 10, 2019FierceBiotech

Harvard-born diabetes startup Semma reports advances in turning stem cells into insulin producers

Semma Therapeutics has faced an obstacle with its process of turning undifferentiated pluripotent ste... See more »
May 8, 2019BioPortfolio

Semma Therapeutics Announces Publication in Nature Demonstrating Advancements in Regenerative Cell Therapy for Type 1 Diabetes

Semma Therapeutics Inc. a biotechnology company pioneering the curative use of stem cells in regenera... See more »

Semma Therapeutics Press Releases

Social Media

Semma Therapeutics Headquarters

100 Technology Square Floor 3

Cambridge, Massachusetts02139

857-529-6430

Driving Directions »

Trending Companies

Semma Therapeutics Summary

ABOUT

Overview

Semma Therapeutics is a biotechnology company that develops and commercializes stem cell-based therapies for the treatment of diabetes. Semma Therapeutics was founded in 2014. Semma Therapeutics' headquarters is located in Cambridge, Massachusetts, US...

CEO

Semma Therapeutics's President & CEO, Bastiano Sanna, currently has an approval rating of 88%. Semma Therapeutics's primary competitors are ViaCyte, Diamyd Medical & Orgenesis.

Frequently Asked Questions about Semma Therapeutics

  1. When was Semma Therapeutics founded?

    Semma Therapeutics was founded in 2014
  2. Who is Semma Therapeutics's CEO?

    Semma Therapeutics's CEO is Bastiano Sanna
  3. How much revenue does Semma Therapeutics generate?

    Semma Therapeutics generates $7M in revenue
  4. How much funding does Semma Therapeutics have?

    Semma Therapeutics has historically raised $162.9M in funding
  1. Where is Semma Therapeutics's headquarters?

    Semma Therapeutics's headquarters is in Cambridge Massachusetts, USA
  2. How many employees does Semma Therapeutics have?

    Semma Therapeutics has 35 employees
  3. What sector does Semma Therapeutics operate in?

    Semma Therapeutics is in Biotechnology
  4. Who are Semma Therapeutics's competitors?

    Semma Therapeutics's top competitors are ViaCyte, Diamyd Medical, Orgenesis